Nasyrov Emil, Seppelfricke Clara, Doycheva Deshka, Gassel Caroline J, Merle David A, Voykov Bogomil
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany.
Ocul Immunol Inflamm. 2024 Dec 6:1-8. doi: 10.1080/09273948.2024.2436101.
To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.
This study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (≥20% IOP reduction, target IOP of 6-21 mmHg). Complete success was considered without IOP-lowering medication or additional surgery other than needling. Qualified success A was considered regardless of medication use, and qualified success B regardless of medication and/or incisional bleb revision. The secondary outcome measures included revision and complication rates.
Twenty-five eyes (viral group: 10 with Fuchs uveitis syndrome and six with herpetic uveitis; juvenile idiopathic arthritis (JIA) group: nine with JIA-related uveitis) were included. The 12-month complete success rate was significantly higher in the viral group than in the JIA group (69% vs 11%; = 0.0059, log-rank test). The qualified success rates in the viral and JIA groups were 75% and 22% for category A ( = 0.029) and 94% and 56% for category B ( = 0.0237), respectively. Among the viral and JIA groups, 13% and 11% required medication, respectively. Incisional bleb revisions were conducted within 12 months in 25% and 78%, respectively ( = 0.0131, log-rank test). Complications were self-limiting, with no uveitic activity observed.
The PMS is safe and effective for glaucoma secondary to viral anterior uveitis. Conversely, it is moderately effective in eyes with JIA-related UG, with a high probability of bleb fibrosis development.
在欧洲人群中研究Preserflo微型分流器（PMS）治疗不同类型葡萄膜炎性青光眼（UG）继发青光眼的疗效和安全性。
本研究评估了连续接受PMS治疗的UG患者的眼睛。主要结局指标为12个月手术成功率（眼压降低≥20%，目标眼压为6 - 21 mmHg）。完全成功定义为无需使用降眼压药物或除针刺外的其他手术。合格成功A定义为无论是否使用药物，合格成功B定义为无论是否使用药物和/或进行切口性滤过泡修复。次要结局指标包括修复率和并发症发生率。
纳入25只眼睛（病毒组：10只患有Fuchs葡萄膜炎综合征，6只患有疱疹性葡萄膜炎；幼年特发性关节炎（JIA）组：9只患有JIA相关葡萄膜炎）。病毒组12个月完全成功率显著高于JIA组（69%对11%；P = 0.0059，对数秩检验）。病毒组和JIA组A类合格成功率分别为75%和22%（P = 0.029），B类分别为94%和56%（P = 0.0237）。病毒组和JIA组分别有13%和11%需要使用药物。分别有25%和78%在12个月内进行了切口性滤过泡修复（P = 0.0131，对数秩检验）。并发症为自限性，未观察到葡萄膜炎活动。
PMS对病毒相关性前葡萄膜炎继发青光眼安全有效。相反，它对JIA相关UG的眼睛中度有效，滤过泡纤维化发生概率较高。
